Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy (Q36302496)

13 August 2017

Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy (English)

1 reference

13 August 2017

1 reference

1 reference

12

Ignacio I Wistuba

1 reference

13 August 2017

13

Stephen G Swisher

1 reference

13 August 2017

11

Ara A Vaporciyan

1 reference

13 August 2017

Apar Pataer

1

1 reference

13 August 2017

Neda Kalhor

2

1 reference

13 August 2017

Arlene M Correa

3

1 reference

13 August 2017

Maria Gabriela Raso

4

1 reference

13 August 2017

Jeremy J Erasmus

5

1 reference

13 August 2017

Edward S Kim

6

1 reference

13 August 2017

Carmen Behrens

7

1 reference

13 August 2017

J Jack Lee

8

1 reference

13 August 2017

Jack A Roth

9

1 reference

13 August 2017

David J Stewart

10

1 reference

13 August 2017

University of Texas M. D. Anderson Lung Cancer Collaborative Research Group

14

1 reference

13 August 2017

1 May 2012

1 reference

Journal of Thoracic Oncology

13 August 2017

1 reference

13 August 2017

7

1 reference

13 August 2017

5

1 reference

13 August 2017

825-832

1 reference

Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

The new lung cancer staging system

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

Histologic Assessment of Non–Small Cell Lung Carcinoma after Neoadjuvant Therapy

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

Grading of tumor regression in non-small cell lung cancer : morphology and prognosis

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3465940

Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients

5 December 2018

1 reference

12 December 2020

Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment

1 reference

12 December 2020

Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer

1 reference

12 December 2020

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

12 December 2020

Induction chemotherapy before surgery for early-stage lung cancer: A novel approach

1 reference

12 December 2020

10.1097/JTO.0B013E318247504A

Identifiers

DOI

1 reference

release_taimkcsmsrct3mqwbnimsgpn4m

13 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/taimkcsmsrct3mqwbnimsgpn4m

24 November 2022

mapped directly with Wikidata item

1 reference

13 August 2017

1 reference